[go: up one dir, main page]

UY33652A - Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4(il-ar) - Google Patents

Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4(il-ar)

Info

Publication number
UY33652A
UY33652A UY33652A UY33652A UY33652A UY 33652 A UY33652 A UY 33652A UY 33652 A UY33652 A UY 33652A UY 33652 A UY33652 A UY 33652A UY 33652 A UY33652 A UY 33652A
Authority
UY
Uruguay
Prior art keywords
interleucine
antibodies
receiver
formulations containing
containing anti
Prior art date
Application number
UY33652A
Other languages
English (en)
Spanish (es)
Inventor
Dix Daniel
Tang Xiaolin
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of UY33652A publication Critical patent/UY33652A/es

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
UY33652A 2010-10-06 2011-10-06 Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4(il-ar) UY33652A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39028310P 2010-10-06 2010-10-06

Publications (1)

Publication Number Publication Date
UY33652A true UY33652A (es) 2012-04-30

Family

ID=45995014

Family Applications (1)

Application Number Title Priority Date Filing Date
UY33652A UY33652A (es) 2010-10-06 2011-10-06 Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4(il-ar)

Country Status (14)

Country Link
AR (1) AR083338A1 (pt)
DK (2) DK2624865T3 (pt)
ES (2) ES2820246T3 (pt)
HK (1) HK1258305A1 (pt)
HR (1) HRP20181822T1 (pt)
HU (1) HUE052089T2 (pt)
LT (1) LT2624865T (pt)
PT (1) PT3354280T (pt)
RS (1) RS57850B1 (pt)
SI (1) SI2624865T1 (pt)
SM (1) SMT201800488T1 (pt)
TW (7) TWI498121B (pt)
UA (1) UA111731C2 (pt)
UY (1) UY33652A (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015003590A8 (pt) 2012-08-21 2017-10-31 Sanofi Sa Métodos para tratamento ou prevenção da asma por administração de um antagonista de il-4r
HUE046410T2 (hu) * 2013-06-21 2020-03-30 Sanofi Biotechnology Eljárások orrpolipózis kezelésére IL-4R-antagonista beadásával
AU2014284235B2 (en) * 2013-06-21 2019-11-21 Regeneron Pharmaceuticals, Inc. Methods for treating nasal polyposis by administering an IL-4R antagonist
WO2016077675A1 (en) 2014-11-14 2016-05-19 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
PL3703818T3 (pl) 2017-10-30 2024-03-25 Sanofi Biotechnology Antagonista IL-4R do zastosowania w sposobie leczenia lub zapobiegania astmie

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
ES2332082B1 (es) * 2008-07-24 2010-10-26 Consejo Superior De Investigaciones Cientificas (Csic) 45% Sistema de alineacion de patrones en un sustrato mediante litografia por estencil.
KR101593726B1 (ko) * 2008-09-10 2016-02-18 니혼 엑스란 고교 (주) 가교 아크릴레이트계 섬유 및 이의 제조방법
CA2754528A1 (en) * 2009-03-06 2010-09-10 Genetech, Inc. Antibody formulation

Also Published As

Publication number Publication date
HK1258305A1 (zh) 2019-11-08
TW201716086A (zh) 2017-05-16
TW202320851A (zh) 2023-06-01
PT3354280T (pt) 2020-09-01
HUE052089T2 (hu) 2021-04-28
DK3354280T3 (da) 2020-09-28
SMT201800488T1 (it) 2018-11-09
TW202026011A (zh) 2020-07-16
TWI690329B (zh) 2020-04-11
TW202102262A (zh) 2021-01-16
TWI856388B (zh) 2024-09-21
TW201221141A (en) 2012-06-01
RS57850B1 (sr) 2018-12-31
ES2687813T3 (es) 2018-10-29
HRP20181822T1 (hr) 2018-12-28
ES2820246T3 (es) 2021-04-20
TWI718890B (zh) 2021-02-11
TW201542229A (zh) 2015-11-16
TWI498121B (zh) 2015-09-01
TWI782325B (zh) 2022-11-01
SI2624865T1 (sl) 2018-10-30
TWI679988B (zh) 2019-12-21
DK2624865T3 (en) 2018-10-22
TW201924718A (zh) 2019-07-01
AR083338A1 (es) 2013-02-21
LT2624865T (lt) 2018-10-25
UA111731C2 (uk) 2016-06-10
TWI568445B (zh) 2017-02-01

Similar Documents

Publication Publication Date Title
ECSP12012092A (es) Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleuquina-6 (il-6r)
CY1121233T1 (el) Σταθεροποιημενα σκευασματα που περιεχουν αντισωματα καtα του υποδοχεα iντερλευκinης-4(ιl-4r)
UY33515A (es) Formulaciones estabilizadas que contienen anticuerpos anti-ngf
CY1122181T1 (el) Φαρμακοτεχνικη μορφη αντισωματος
AR122746A2 (es) Una formulación farmacéutica líquida estable de anticuerpo
CO2019011021A2 (es) Formulacion estable de anticuerpos
MX357393B (es) Formulaciones estabilizadas que contienen anticuerpos anti - ang2.
MY157772A (en) Antibody formulation
MX375672B (es) Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9.
CR10555A (es) Vacunas para malaria
MX2009005414A (es) Formulaciones liquidas de anticuerpo antirrabico.
UY33652A (es) Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4(il-ar)
CO2021011648A2 (es) Formulaciones estabilizadas que contienen anticuerpos anti-il-33
TN2012000342A1 (en) Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies
EA202090016A2 (ru) Стабилизированные композиции, содержащие антитела к рецептору интерлейкина-4 (il-4r)
TH175929A (th) สูตรตำรับของแอนติบอดี้ (Antibody Formulation)